

Result No.	Score	Query Match	Length	DB ID	Description
1	4880	99.3	919	18 AAW14783	Androgen receptor.
2	4880	99.3	919	21 AAY7914	Human androgen rec
3	4880	99.3	919	23 AAE1961	Human androgen rec
4	4872	99.3	919	10 AAY93109	Human androgen rec
5	4885	98.5	918	20 AAY33491	Human androgen rec
6	4827.5	98.3	918	12 AAR12223	Human androgen rec
7	4814	98.0	919	10 AAY93996	Human androgen rec
8	4201.5	83.5	902	10 AAP91006	Rat androgen recep
9	4200.5	83.5	902	10 AAP93110	Rat androgen recep
10	4187.5	85.3	902	12 AAR12224	Rat androgen recep

SUMMARIES

Run on:	Title:	Perfect score:	Sequence:	Scoring table:	Post-processing:	Database :	Total number of hits satisfying chosen parameters:	Minimum DB seq length:	Maximum DB seq length:	Maximum Match 100%	Maximum Match 100%	Listing first 45 summaries	RESULTS	ALIGNMENTS
April 28, 2003, 13:48:10 ;	US-09-497-822c-19	4912	1 METVQGLGRRVPRPPSKTIR.....SVQVPKILSGKVKP1YFHTQ 923	BLOSUM62	Minimum Match 100% Maximum Match 100%	A_Genesed_101002.*	908470	0	2000000000	10	10	1: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1980.DAT;*	RESULT 1 AAW14783	
(without alignments)				Gapext: 0.5								2: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1981.DAT;*	ID AAW14783 standard; Protein: 919 AA.	
2795/235 Million cell updates/sec				Gapop 10.0 , Gapext: 0.5								3: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1982.DAT;*	XX	
				Searched: 908470 seeds, 133250620 residues								4: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1983.DAT;*	AC AAW14783;	
												5: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1984.DAT;*	XX	
												6: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1985.DAT;*	XX	
												7: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1986.DAT;*	XX	
												8: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1987.DAT;*	XX	
												9: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1988.DAT;*	XX	
												10: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1989.DAT;*	XX	
												11: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1990.DAT;*	XX	
												12: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1991.DAT;*	DE Androgen receptor.	
												13: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1992.DAT;*	XX	
												14: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1993.DAT;*	XX	
												15: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1994.DAT;*	XX	
												16: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1995.DAT;*	XX	
												17: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1996.DAT;*	XX	
												18: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1997.DAT;*	XX	
												19: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1998.DAT;*	XX	
												20: /SIDS2/gcdata/genesed/geneseqp-emb1/AA1999.DAT;*	XX	
												21: /SIDS2/gcdata/genesed/geneseqp-emb1/AA2000.DAT;*	XX	
												22: /SIDS2/gcdata/genesed/geneseqp-emb1/AA2001.DAT;*	XX	
												23: /SIDS2/gcdata/genesed/geneseqp-emb1/AA2002.DAT;*	XX	

pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result, and is derived by analysis of the total score distribution.

Result No.	Score	Query Match	Length	DB ID	Description
1	4880	99.3	919	18 AAW14783	Androgen receptor.
2	4880	99.3	919	21 AAY7914	Human androgen rec
3	4880	99.3	919	23 AAE1961	Human androgen rec
4	4872	99.3	919	10 AAY93109	Human androgen rec
5	4885	98.5	918	20 AAY33491	Human androgen rec
6	4827.5	98.3	918	12 AAR12223	Human androgen rec
7	4814	98.0	919	10 AAP93996	Human androgen rec
8	4201.5	83.5	902	10 AAP91006	Rat androgen recep
9	4200.5	83.5	902	10 AAP93110	Rat androgen recep
10	4187.5	85.3	902	12 AAR12224	Rat androgen recep

Copyright (c) 1993 - 2003 Compugen Ltd.	Ligand binding dom
	Fused androgen rec
	Human androgen rec
	Human androgen rec
	"TrP"/androgen rec
	Rat androgen recep
	TrP/androgen rec
	Ligand binding dom
	Human progesterone
	Androgen receptor
	Human unliganded
	Human progesterone
	Sequence of the hu
	Green fluorescent
	Sequence of the pr
	: ligand binding dom
	Mutant nuclear glu
	Androgen independe
	Human unliganded
	Rat 2-progesterone
	Truncated GAL4 DBD
	Geneswitch regulat
	Chain A of structu
	Geneswitch regulat
	Chimeric Cre LDB-G
	iCRE-FRR-GBD*
	Chain A of structu
	Glucocorticoid rec
	A rat glucocortico
	Glucocorticoid rec
	Rat glucocorticoid
	Rat glucocorticoid rec
	OS Homo sapiens.
	XX WO9711170-A1.
	PD 27-MAR-1997.
	XX XX 20-SEP-1996; 96WO-US15081.
	PR 20-SEP-1995; 95US-0004018.
	PA (WORC-) WORCESTER FOUND BIOMEDICAL RES.
	XX XX PI Zamecnik PA;
	XX XX DR WPI; 1997-202879/18.
	DR N-PSDB; AAT63407.
	PT Oligonucleotide(s) antisense to human androgen receptor and acidic FGF genes - used to inhibit gene expression, for the treatment of
	PT benign prostatic hyperplasia

481	VAPGYTTRPQQLAGQESDFTADPVWYFGGMYSRVPYPSPTCVKSEMPWNDSSCPYGD	540
477	VAPGYTTRPQQLAGQESDFTADPVWYFGGMYSRVPYPSPTCVKSEMPWNDSSCPYGD	536
541	MRLETARDHVLPIDYFPQPKTCLJCDEASGCHYGAUTCGSCKVFFKRAEGKOKYLCA	600
537	MRLETARDHVLPIDYFPQPKTCLJCDEASGCHYGAUTCGSCKVFFKRAEGKOKYLCA	596
601	SRNDCTIDKPRRKNCPSCLRKCYEAGMTLGARKLKKGNLKLQEGEASSTSPRETT	660
597	SRNDCTIDKPRRKNCPSCLRKCYEAGMTLGARKLKKGNLKLQEGEASSTSPRETT	656
661	QKLTVSHIEGECQIFNLVLEAIEPGVYCAGHDNNQPDSPFAALLSSNELGERQLYHVV	720
657	QKLTVSHIEGECQIPNLVLEAIEPGVYCAGHDNNQPDSPFAALLSSNELGERQLYHVV	716
721	KWAALKALPGRFLNHVDQMAVITYQSYWNGLMNVFAMGWRSPFTNVNSRMLYFAPDLYFNEYRMH	780
717	KWAALKALPGRFLNHVDQMAVITYQSYWNGLMNVFAMGWRSPFTNVNSRMLYFAPDLYFNEYRMH	776
781	KSRMYSOCVRMRHLISOEFGNQIQTPEQFLCMKALLFLSTIPDGLKNOKFDELRYNIK	840
777	KSRMYSOCVRMRHLISOEFGNQIQTPEQFLCMKALLFLSTIPDGLKNOKFDELRYNIK	836
841	ELDRJACKRNPTCSRRYQIQLLDSDVQPIARELHOFTFDLLIKSHMVSDFPEMNA	900
837	ELDRJACKRNPTCSRRYQIQLLDSDVQPIARELHOFTFDLLIKSHMVSDFPEMNA	896
901	EITSVQPKLISGKVPKPYHTQ	923
897	FITTSVQPKLISGKVPKPYHTQ	919

RESULT 4
AP3109 D AAP3109 standard; protein: 919 AA.

XX OS Homo sapiens.
 XX PN W09926966-A2.
 XX PD 03-JUN-1999.
 XX PF 25-NOV-1998; 98W0-US25296.
 XX PR 26-NOV-1997; 97US-0980115.
 XX PA (RECC) UNIV CALIFORNIA.
 XX PI Aprietti JW, Baxter JD, Fletterick RJ, Kushner PJ;
 Scanian TS, Shiu AK, Wagner RL, West BL;
 DR WPI: 1999-357810/30.
 XX PT Modulating activity of a thyroid hormone receptor
 XX PS Disclosure; Fig 3H-R; 447pp; English.
 XX CC The invention relates to a method for modulating activity of a thyroid hormone receptor that comprises administration of an aromatic compound which fits spatially and preferentially into a thyroid hormone ligand binding domain. The aromatic compound (of a specified formula) can be used to increase alpha-glycerophosphate dehydrogenase (GPDH) levels and are levels which do not significantly modify cardiac GPDH levels and are indicated in the treatment of obesity. The compound also lower total plasma cholesterol and triglyceride levels and can be used as anti-hypertriglyceridemic agents. The compound may also be used for treating atherosclerosis and may be indicated in thyroid hormone replacement therapy in patients with compromised cardiac function. Sequences AAY161-636 amino acid sequences of ligand binding domains of several members of the nuclear receptor superfamily.
 XX SQ Sequence 452 AA;
 Query Match 49.5%; Score 2429; DB 20; Length 452;
 Best Local Similarity 99.8%; Pred. No. 1.2e-155;
 Matches 451; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 QY 472 GGGGEAGAVAPYGYTRPPQGLAGQESDFTADPVWYPGGMVSRVPSPTCVKSEMGPMM 531
 Db 1 GGGGEAGAVAPYGYTRPPQGLAGQESDFTADPVWYPGGMVSRVPSPCVKSEMGPMM 60
 QY 532 DSYSGPYGDMRLETDARDHVLPIDYFPQPQKCLICDEASCHYGAUTCGSCKVYFFKRA 591
 Db 61 DSYSGPYGDMRLETDARDHVLPIDYFPQPQKCLICDEASCHYGAUTCGSCKVYFFKRA 120
 QY 592 EGKOKYLCASRNDCDTIKFRRKNCPSCRLRKCYEAGMTLGARKLKLNKLQGEAEASS 651
 Db 121 EGKOKYLCASRNDCDTIKFRRKNCPSCRLRKCYEAGMTLGARKLKLNKLQGEAEASS 180
 QY 652 TTSPTEETTQKLTVSHLEGYECOPILNVLATEPGVCAHDNNQDPSAALLSSINEL 711
 Db 181 TTSPTEETTQKLTVSHLEGYECOPILNVLATEPGVCAHDNNQDPSAALLSSINEL 240
 QY 712 GEROLVHVKWAKALPGERFLNHYDDQMAVIQYSWMGLMFAANGWRSPITNNSRMLYFAPD 771
 Db 241 GEROLVHVKWAKALPGERFLNHYDDQMAVIQYSWMGLMFAANGWRSPITNNSRMLYFAPD 300
 Db 301 LVNEYRMHKRSRKYSOCYVRMHLSQEQFLPQEFCLMKAALLFSIIPYDGLKQKF 360
 QY 772 LVNEYRMHKRSRKYSOCYVRMHLSQEQFLPQEFCLMKAALLFSIIPYDGLKQKF 831
 Db 832 DELRMNYIKELDRITACKKNPFTCSRRYQFQYQTLKLDSVOPTAREHQTDFLLIKSHMV 891
 Db 361 DELRMNYIKELDRITACKKNPFTCSRRYQFQYQTLKLDSVOPTAREHQTDFLLIKSHMV 420
 QY 892 SVDPEMMAEISVQVPKLSGKVPKYFHTQ 923
 Db 421 SVDPEMMAEISVQVPKLSGKVPKYFHTQ 452
 XX RESULT 12
 AAG68238 standard; Protein; 839 AA.
 ID AAG68238
 XX
 AC AAG68238;
 XX DT 08-FEB-2002 (first entry)
 XX DE Fused androgen receptor (AR) protein SEQ ID NO:11.
 XX Human; androgen receptor; AR; fused androgen receptor protein;
 KW fusion androgen receptor protein; sugar-combining protein;
 KW maltose-combining protein.
 XX Chimeric - Homo sapiens.
 OS Chimeric - Unidentified.
 XX PN JP2001252080-A.
 XX PD 18-SEP-2001.
 XX PF 13-MAR-2000; 2000JP-0069030.
 XX PR 13-MAR-2000; 2000JP-0069030.
 XX PA (TOMY) TOKYO KR.
 XX WPI; 2002-029658/04.
 DR NPDB; ABA1683.
 XX DR
 XX PT New polypeptide for screening drugs, comprises an androgen receptor protein fused with a sugar combining protein.
 PT Protein fused with a sugar combining protein.
 XX Claim 8; Page 11-13; 16pp; Japanese.
 PS
 XX CC The present invention describes a fused androgen receptor (AR) protein prepared by fusing an androgen receptor protein with a sugar combining protein. Also described are: (1) a gene encoding the above fused AR protein; (2) a vector carrying the above gene; (3) a transformant in which the above vector is introduced to a microbe and a gene encoding the fused AR protein is expressed; (4) the preparation of a fused AR protein in which the above transformant is cultured and the fused AR protein is collected from the resultant culture; and (5) a reagent for detecting the presence of interaction with a ligand containing the above fused AR protein, a solvent for dissolving chemical substances and a diluent liquid of the dissolved chemical substances. The fusion protein can be used for screening drugs. The present sequence represents the AR protein and sugar-combining protein fusion protein from the present invention.
 XX Sequence 839 AA;
 SQ Query Match 48.9%; Score 2401; DB 23; Length 839;
 Best Local Similarity 99.3%; Pred. No. 2e-153;
 Matches 446; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 475 GGEAGAVAPYGYTRPPQGLAGQESDFTADPVWYPGGMVSRVPSPTCVKSEMGPMDY 534
 Db 391 GSEAGAVAPYGYTRPPQGLAGQESDFTADPVWYPGGMVSRVPSPTCVKSEMGPMDY 450
 QY 535 SGPYGDMRLETDARDHVLPIDYFPQPQKCLICDEASCHYGAUTCGSCKVYFFKRAEGK 594
 Db 451 SGPYGDMRLETDARDHVLPIDYFPQPQKCLICDEASCHYGAUTCGSCKVYFFKRAEGK 510
 Db 391 GSEAGAVAPYGYTRPPQGLAGQESDFTADPVWYPGGMVSRVPSPTCVKSEMGPMDY 450
 QY 595 QKYLCAQRNDCTIKFRRKNCPSCRLRKCYEAGMTLGARKLKLNKLQGEAEASS 654
 Db 511 QKYLCAQRNDCTIKFRRKNCPSCRLRKCYEAGMTLGARKLKLNKLQGEAEASS 570
 QY 655 PTEETTQKLTVSHLEGYECOPILNVLATEPGVCAHDNNQDPSAALLSSINEL 714
 Db 571 PTEETTQKLTVSHLEGYECOPILNVLATEPGVCAHDNNQDPSAALLSSINEL 630

Qy	715	OLVHVVVKWAKALPGRFLNHYDDOMAVIQYSWMGLMVEANGWRSPFTNVNSRMLYFAPDLVF	774	Query Match Score 41.3%; Best Local Similarity 97.2%; Pred. No. 8.7e-129; Matches 383; Conservative 1; Mismatches 1; Indels 9; Gaps 1;
Db	631	OLVHVVVKWAKALPGRFLNHYDDOMAVIQYSWMGLMVEANGWRSPFTNVNSRMLYFAPDLVF	690	
Qy	775	NEYRMHKSRMYSQCVRMRHLSQEFSWQLQTPEFLCMKALLFSTIPDGLKNOKEFFDEL	834	Qy 530 WMDSYSGPYGDNRLETTARDHVLPIIDYYFPPTCLICGDEASGHYGAATCGSCKVFFKR 589
Db	691	NEYRMHKSRMYSQCVRMRHLSQEFSWQLQTPEFLCMKALLFSTIPDGLKNOKEFFDEL	750	Db 4 WLHS-----LETARDHVLPIIDYYFPPTCLICGDEASGHYGAATCGSCKVFFKR 54
Qy	835	RMNYYKELDRITACKRKNPNTCSRRFYQTKLUDSVOPTAARELHQFTDILLKSHMYSVD	894	Qy 590 AAEGKQYKLCASRNDCDTDKPERKNPSCSRURKCYZAGMTLGARKLKGKLNKLQEGEA 649
Db	751	RMNYYKELDRITACKRKNPNTCSRRFYQTKLUDSVOPTAARELHQFTDILLKSHMYSVD	810	Db 55 AAEGKQYKLCASRNDCDTDKPERKNPSCSRURKCYZAGMTLGARKLKGKLNKLQEGEA 114
Qy	895	FPEMMAEILSVQVPKTSRRFYQTKLUDSVOPTAARELHQFTDILLKSHMYSVD	923	Qy 650 STTTSPTEETTQKLTVTHSIEGYCQIFLNLYEATPGVIVCAHGDNINQPSFAAIISSLN 709
Db	811	FPEMMAEILSVQVPKTSRRFYQTKLUDSVOPTAARELHQFTDILLKSHMYSVD	839	Db 115 STTTSPTEETTQKLTVTHSIEGYCQIFLNLYEATPGVIVCAHGDNINQPSFAAIISSLN 174
RESULT 13				
ABB83821	ID	ABB83821 standard; Protein; 388 AA.		
XX	XX			
AC	ABB83821;			
XX	XX			
DT	13-SEP-2002	(first entry)		
XX	XX			
DE	Human androgen receptor variant AR42	SEQ ID NO 2.		
XX	XX			
KW	Human; androgen receptor; receptor; AR; AR42; AR32; tumour; cancer;			
KW	steroid response element; prostate cancer; prostate; gene therapy;			
KW	hormone therapy; cytostatic; contraceptive.			
OS	Homeo sapiens.			
XX	XX			
PN	EP1213300-A1.			
XX	XX			
PD	12-JUN-2002.			
XX	XX			
PF	26-OCT-2001; 2001EP-0250379.			
XX	XX			
PR	30-NOV-2000; 2000DE-1061161.			
XX	XX			
PA	(SCHHD) SCHERING AG.			
XX	XX			
PI	Ahrens-Fath I, Haendler B;			
XX	XX			
DR	WPI; 2002-530575/57.			
DR	N-PSDB; ABN85656.			
XX	XX			
PT	New nucleic acid encoding variant forms of androgen receptor; useful			
PT	for diagnosis and treatment of prostatic cancer, also related proteins			
XX	XX			
PS	Claim 5; Page 9-11; 25pp; German.			
XX	XX			
CC	The invention relates to a nucleic acid (I) that encodes an androgen			
CC	receptor (AR) variant AR42 (ABN85656) or AR32 (ABN85657) or its			
CC	equivalents or a sequence that hybridises to them under stringent			
CC	conditions. Polypeptides (II, ABB83821-ABB83822) expressed by (I), can			
CC	bind androgens and other ligands and form heterodimers which can bind to			
CC	so act as repressors of target genes but do not induce activation,			
CC	antibodies. (I) are used to raise specific			
CC	for detecting (I)-related nucleic acid in tumour tissue. Also (I), (II),			
CC	a specific peptide and cells transfected with (I)-containing vectors, are			
CC	useful for identifying effectors of (II), specifically antiandrogenic			
CC	agents potentially useful for treating androgen-related diseases, e.g.			
CC	cancer of prostate or testis and as male contraceptives. (I) can be used			
CC	similarly in gene therapy. Antibodies to (II) are used to detect or			
CC	quantify (II) in tumour tissue, e.g. to determine if resistance to			
XX	hormone therapy is the result of altered expression of (II).			
SQ	Sequence 388 AA;			

The invention relates to a nucleic acid (I) that encodes an androgen receptor (AR) variant AR42 (ABN85656) or AR32 (ABN85657) or its receptor (AR) variant AR42 (ABN85656) or AR32 (ABN85657) or its

Claim 5; Page 11-12; 25pp; German.

